Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5934647 | 0.93 | MEN1 (0.41) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL5229523 | 0.93 | MEN1 (0.41) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL14416213 | 0.93 | MEN1 (0.41) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL31527127 | 0.88 | MEN1 (0.42) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL13525930 | 0.88 | KMT2A (0.38) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL10040060 | 0.88 | KMT2A (0.38) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL298008 | 0.88 | KMT2A (0.38) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL1219830 | 0.87 | KMT2A (0.39) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL1088268 | 0.85 | MEN1 (0.40) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL4966238 | 0.85 | MEN1 (0.40) | MEN1MAPK1KMT2ANFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8834841-B2 | Imaging agents | EMORY UNIVERSITY (US) | 2014-09-16 | — | — | US | disclosed |
| US-20130225828-A1 | IMAGING AGENTS | EMORY UNIVERSITY (US) | 2013-08-29 | — | — | US | disclosed |
| US-8435493-B2 | Imaging agents | EMORY UNIVERSITY (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110144483-A1 | IMAGING AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-16 | — | — | US | disclosed |
| US-7837982-B2 | Imaging agents | EMORY UNIVERSITY (US) | 2010-11-23 | — | — | US | disclosed |
| US-20070082879-A1 | Imaging Agents | EMORY UNIVERSITY (US) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144483-A1 | IMAGING AGENTS | SLC7A1, SSTR1, SSTR3 | MEN1 91/4885MAPK1 4278/4885KMT2A 2212/4885 |
| US-20070082879-A1 | Imaging Agents | SLC7A1, SSTR1, SSTR3 | MEN1 91/4885MAPK1 4278/4885KMT2A 2212/4885 |
| US-20130225828-A1 | IMAGING AGENTS | SLC7A1, SSTR1, SSTR3 | MEN1 91/4885MAPK1 4280/4885KMT2A 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.